Skip to main content
Sign In

Jennifer Kiser, PharmD, PhD

Associate Professor, Department of Pharmaceutical Sciences

Associate Director, Center for Translational Pharmacokinetics and Pharmacogenomics

Mailing address:

University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
Mail Stop C238
12850 E. Montview Blvd. V20-4102
Aurora, CO 80045

Office Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Fourth Floor
Room 4102

Lab Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Fourth Floor
Room 4420A(S)


Training and Education:

  • 7/2011-5/2019 - Doctor of Philosophy in Clinical Sciences, University of Colorado, Aurora, CO
  • 7/2003-1/2006 - Antiretroviral Clinical Pharmacology Fellowship; University of Colorado Denver, Denver, CO
  • 6/2001-6/2002 - Pharmacy Practice Residency; University of California San Diego Medical Center, San Diego, CA
  • 8/1997-5/2001 - Doctor of Pharmacy University of North Carolina Chapel Hill, Chapel Hill, North Carolina

Clinical / Research Interests:

My research is aimed at determining concentration-effect relationships and conducting drug interaction studies with antiviral drugs. I am particularly interested in characterizing antiviral pharmacology in persons with viral hepatitis and HIV-infected special patient populations including infants, children, adolescents, and pregnant women and persons coinfected with viral hepatitis. Our laboratory is a leader in development and application of state-of-the-art methods for quantifying antiviral drugs in various biologic matrices.


Professional Program

  • PHRD 7085 Pharmacotherapy 6
  • PHRD 6925 Medicinal Chemistry
  • PHRD 6915 & PHRD 7015 Seminar Research Course

Graduate Program

  • PHSC 7330 Development of Drugs and Biologics
  • PHSC/TXCL 7665 Pharmacokinetic Principles and Applications
  • TXCL 7561 Drug Metabolism & Pharmacogenetics

Selected Original Research Publications:

  1. AASLD/IDSA HCV Guidance Panel. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus. Hepatology EPub 2015 Jun 25.
  2. Rower JE, Meissner EG, Jimmerson LC, Osinusi A, Sims Z, Petersen T, Bushman LR, Wolfe P, McHutchison JG, Kottilil S, Kiser JJ*. Serum and cellular ribavirin pharmacokinetic and concentration effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother. EPub 2015 May 1.
  3. Wu LS, Rower JE, Burton JR Jr, Anderson PL, Hammond KP, Baouchi-Mokrane F, Everson GT, Urban TJ, D'Argenio DZ, Kiser JJ*. Population pharmaockinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2015;59(4):2179-88.
  4. Jimmerson LC, Ray ML, Bushman LR, Anderson PL, Klein B, Rower JE, Zheng J-H, Kiser JJ*. Determination of Intracellular Ribavirin Mono-, Di-, and Triphosphate Concentrations by Solid Phase Extraction and HPLC-MS-MS Detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;978-979:163-72.
  5. Moorehead KJ, Burton JR, Jr., Everson GT, J-H Zheng, Kerr BJ, Bushman LR, Wang M, Ju C, Nydam T, Kiser JJ*. Intrahepatic Antiviral Quantification in a Patient Undergoing Orthotopic Cadaveric Liver Transplantation. J Antimicrob Chemother. 2015;70(1):315-7.
  6. Jimmerson LC, Zheng J-H, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ*. Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry. J Chrom B 2014;944:18-24.
  7. Hammond KP, Nielsen C, Linnebur SA, Langness JA, Ray G, Maroni P, Kiser JJ*. Priapism Induced by Boceprevir-CYP3A4 inhibition and Alpha-Adrenergic Blockade. Clinical Infectious Diseases 2014;58(1):e35-8.
  8. Hammond KP, Wolfe P, Burton JR, Predhomme JA, Ellis CM, Ray ML, Bushman LR, Kiser JJ*. Pharmacokinetic Interaction between Boceprevir and Etravirine in HIV/HCV Seronegative Volunteers. JAIDS 2013;62(1):67-73.
  9. Kiser JJ, Zhu R, D’Argenio DZ, Cotton MF, Bobat R, McSherry GD, Madhi SA, Carey VJ, Seifart HL, Werely CJ, Fletcher CV*. Isoniazid Pharmacokinetics, Pharmacodynamics, and Dosing in South African Infants. Therapeutic Drug Monitoring 2012;34(4):446-51.
  10. Bushman LR, Kiser JJ, Rower JR, Klein B, Zheng JH, Ray M, Anderson PL*. Determination of nucleoside analog mono-, di, and triphosphates in cellular matrix by solid phase extraction and ultrasensitive LC/MS/MS detection. Journal of Pharmaceutical and Biomedical Analysis 2011;56(2):390-401.
  11. Kiser JJ, Rutstein RM, Samson P, Graham B, Mofenson L, Smith E, Fenton T, Brundage RC, Fletcher CV*. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents; Infant Maternal Pediatric Adolescent AIDS Clinical Trials Group P1020A. AIDS 2011;25(12):1489-96.
  12. Kiser JJ*, Bumpass JB, Meditz AL, Anderson PL, Bushman L, Ray M, Predhomme JA, Rower J, MaWhinney S, Brundage R. Effect of Antacids on the Pharmacokinetics of Raltegravir in Human Immunodeficiency Virus Seronegative Volunteers. Antimicrobial Agents and Chemotherapy 2010;54(12):4999-5003.
  13. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW*. Drug: Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers. JAIDS 2008; 47(5):570-578.
  14. Kiser JJ, Aquilante CL, Anderson PL, King T, Carten ML, Fletcher CV*. Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-Infected Patients. JAIDS 2008; 47(3):298-303.
  15. Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris RD, Havens PL*, and the Adolescent Trials Network for HIV/AIDS Interventions. Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and Atazanavir/Ritonavir in Adolescents and Young Adults with HIV Infection – ATN056. Antimicrobial Agents and Chemotherapy 2008;52(2):631-7.
  16. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahnuty T, Bushman L, Fletcher CV*. The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-Infected Patients. Clinical Pharmacology and Therapeutics 2008;83(2):265-272.

Recent Reviews:

  1. Kiser JJ*, Burton JR, Everson GT. Drug interactions in viral hepatitis. Nature Reviews Gastroenterology & Hepatology 2013;10(10):596-606.
  2. Kiser JJ*, Flexner CW. Direct Acting Antiviral Agents for Hepatitis C Virus Infection. Annual Reviews in Pharmacology and Toxicology 2013;53:427-49.
  3. Kiser JJ*, Burton JR, Anderson PL, Everson GT. Review and Management of Drug Interactions with Boceprevir and Telaprevir. Hepatology 2012;55(5):1620-8.
  4. Anderson PL, Kiser JJ, Gardner E, Rower J, Meditz A, Grant R. Pharmacologic considerations for tenofovir and emtricitabine to prevent HIV infection. Journal of Antimicrobial Chemotherapy 2011;66:240-250.

Recent Publications

Center for Translational Pharmacokinetics and Pharmacogenetics